Abstract
53BP2 was initially identified as a protein interacting with p53 in a yeast two-hybrid screen and subsequently shown to enhance p53 transcriptional transactivation and induce apoptosis when transiently overexpressed in cell lines. In order to further study the biologically relevant effects of 53BP2, we have constructed HEK293 stable cell lines where 53BP2 expression can be regulated using an ecdysone inducible expression system. Our results indicate that the response of cells is dependent on the amount of 53BP2 that is expressed. High levels of 53BP2 expression (⩾140-fold above endogenous) impede cell cycle progression and induce apoptosis. Lower levels of 53BP2 expression (6–11-fold above endogenous) suppress colony formation but do not lead to detectable perturbations in the cell cycle or apoptosis. Lower levels of 53BP2 expression sensitized cells to apoptosis induced by DNA damaging chemotherapy agents doxorubicin, ara-C and VP16, but not microtubule active agents paclitaxel and vinblastine. Our results demonstrate that high levels of 53BP2 expression have profound biological effects ultimately leading to apoptosis, whereas lower levels of 53BP2 expression have more subtle effects on growth and sensitize cells to some chemotherapy agents.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Chen X, Ko LJ, Jayaraman L, Prives C . 1996 Genes Dev. 10: 2438–2451
el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B . 1993 Cell 75: 817–825
Gorina S, Pavletich NP . 1996 Science 274: 1001–1005
Helps NR, Barker HM, Elledge SJ, Cohen PTW . 1995 FEBS Lett. 377: 295–300
Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, Kinzler KW, Vogelstein B . 1997 Mol. Cell. 1: 3–11
Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ . 1990 Nature 348: 334–336
Iwabuchi K, Bartel PL, Li B, Marraccino R, Fields S . 1994 Proc. Natl. Acad. Sci. USA 91: 6098–102
Iwabuchi K, Li B, Massa HF, Trask BJ, Date T, Fields S . 1998 J. Biol. Chem. 273: 26061–26068
Levine AJ . 1997 Cell 88: 323–331
Lopez CD, Ao Y, Rohde LH, Perez TD, O'Connor DJ, Lu X, Ford JM, Naumouski L . 2000 Mol. Cell. Biol. 20: 8018–8025
Naumovski L, Cleary ML . 1994 Blood 83: 2261–2267
Naumovski L, Cleary ML . 1996 Mol. Cell. Biol. 16: 3884–3892
Yang J-P, Hori M, Takahashi N, Kawabe T, Kato H, Okamoto T . 1999 Oncogene 18: 5177–5186
Acknowledgements
We thank C Lopez for useful suggestions, Drs X Lu and D O'Connor for mouse anti-53BP2 antibody and Dr Carol Clayberger for anti-Hsc70 antibody. This work was supported by NIH grant CA 76316 to L Naumovski and by NRSA grant HL09552 to LH Rohde.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ao, Y., Rohde, L. & Naumovski, L. p53-interacting protein 53BP2 inhibits clonogenic survival and sensitizes cells to doxorubicin but not paclitaxel-induced apoptosis. Oncogene 20, 2720–2725 (2001). https://doi.org/10.1038/sj.onc.1204352
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204352
Keywords
This article is cited by
-
Highly homologous proteins exert opposite biological activities by using different interaction interfaces
Scientific Reports (2015)
-
Rank-based predictors for response and prognosis of neoadjuvant taxane-anthracycline-based chemotherapy in breast cancer
Breast Cancer Research and Treatment (2013)
-
ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia
Oncogene (2006)
-
ASPPs and cancer
Nature Reviews Cancer (2006)
-
The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells
Leukemia (2003)